All news

Pomerantz probes Foghorn over halted drug and staff cuts

Alpha Vantage · Pluang · · AI-summarised by FinFlash

Pomerantz LLP is investigating Foghorn Therapeutics for potential securities fraud after the company halted its FHD-909 drug program and announced a 40% staff reduction, sending shares down nearly 31%. The probe will examine whether the company and its executives engaged in unlawful business practices. Foghorn plans to prioritize other proprietary programs and aims to fund them through mid-2029.

Read original source

FHTX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.